Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with prostate adenocarcinoma (a specific type of prostate cancer) confirmed by a biopsy
- People whose prostate cancer is classified as "low risk" based on a standard medical scoring system called d'Amico — meaning the cancer is at an early stage (T1–T2a), a PSA blood test result below 10 ng/ml, and a Gleason score of 6
- People whose prostate cancer is classified as "intermediate risk" using the same d'Amico system, but only if the Gleason score is not 7 with a pattern of (4+3)
- People for whom a specialist medical team meeting has agreed that a type of internal radiation treatment called brachytherapy is an appropriate curative treatment
Who may not be able to join:
- People who are currently receiving hormone-blocking treatment (androgen deprivation therapy)
- People for whom brachytherapy using Iodine-125 seeds in the prostate is not medically suitable — for example, if the prostate is larger than 50cc in volume, or if general anaesthesia is not possible
- People for whom an MRI scan is not safe or possible — for example, due to severe claustrophobia or having a pacemaker
- People who are already taking part in another research study that could affect this trial's treatment or results
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Renaud De Crevoisier, PR, Centre Eugène Marquis
Phone: +33(0)299253036
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cost-utility analysis of SBRT compared to "standard" Iodine 125 brachytherapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.